Target · Long-term · 3 — Other
2019 → 2045 · published 2021-10-28
AstraZeneca also commits to reduce absolute scope 3 GHG emissions 90% by FY2045 from a FY2019 base year.
SBTi company profile · UK
AstraZeneca
Pharmaceuticals, Biotechnology and Life Sciences Corporate
Validated Targets
Data: Science Based Targets initiative Target Dashboard, as at 2026-10-08
LocationUnited Kingdom of Great Britain and Northern Ireland
RegionNorthern Europe
SectorPharmaceuticals, Biotechnology and Life Sciences
Organisation typeCorporate
Near-term statusValidated Targets
Near-term target1.5°C · 2030
Long-term statusValidated Targets
Long-term target1.5°C · 2045
Net-zero statusValidated Targets
Net-zero target year2045
Business Ambition for 1.5°CBA1.5 member
ISIN in SBTi dataYes
Published records
Targets and commitments
The records below are reproduced from the Science Based Targets initiative Target Dashboard. A validated target is not evidence that emissions have fallen; progress requires the company’s reported emissions.
Target · Net-zero · 1+2+3 — Other
2015 → 2045 · 1.5°C · published 2021-10-28
Global biopharmaceutical company AstraZeneca commits to reach net-zero greenhouse gas emissions across the value chain by FY2045.
Target · Near-term · 1+2 — Other
2015 → 2026 · 1.5°C · published 2021-10-28
Global biopharmaceutical company AstraZeneca commits to reduce absolute scope 1 and 2 GHG emissions 98% by FY2026 from a FY2015 base year
Target · Near-term · 3 — Other
2019 → 2030 · published 2021-10-28
AstraZeneca commits to reduce absolute scope 3 GHG emissions 50% by FY2030 from a FY2019 base year.
Target · Near-term · 3 — Other
2019 → 2030 · published 2021-10-28
Within this target, AstraZeneca commits to reduce absolute scope 3 GHG emissions from fuel and energy related activities, upstream leased assets and downstream leased assets 80% by FY2030, from a 2019 base year.
Target · Near-term · 3 — Other
2019 → 2030 · published 2021-10-28
AstraZeneca commits to reduce absolute scope 3 GHG emissions from use of sold products 95% by FY2030, from a 2019 base year.
Target · Near-term · 3 — Other
2019 → 2030 · published 2021-10-28
AstraZeneca commits to reduce absolute scope 3 GHG emissions from upstream transportation and distribution, waste generated in operations, business travel, employee commuting and end of life treatment of sold products 46% by FY2030, from a 2019 base year.
Target · Near-term · 3 — Other
2019 → 2025 · published 2021-10-28
Furthermore, AstraZeneca commits that 95% of its suppliers by spend covering purchased goods and services and capital goods will have science-based targets by FY2025.
Target · Near-term · 3 — Other
2019 → 2025 · published 2021-10-28
AstraZeneca commits that 50% of its suppliers by spend covering upstream transportation and distribution and business travel, will have science-based targets by FY2025.
Commitment — Validated Targets